The case for & against
Bull & Bear analysis
Johnson & Johnson (NYSE: JNJ) is a quintessential player in the global healthcare sector, acting as a leading provider of pharmaceuticals, medical devices, and consumer health products. The company boasts a diversified portfolio with a strategic focus on high-growth markets including oncology, immunology, neuroscience, and cardiovascular health. Johnson & Johnson has made significant strides in innovative treatments and market leadership, leveraging a robust pipeline and extensive research and development capabilities to drive growth.
Bull says
- ↑Q1 revenue $24.1 B (+6.4% YoY); Innovative Medicines +7.4%, MedTech +4.6%
- ↑Icotide reached 1,500+ prescriptions, boosting psoriasis market share
- ↑Guidance affirms $100 B revenue target by 2026; FCF ~$1.5 B in Q1
- ↑Dividend up 3.1% this quarter (1.02% yield), 64th straight year of hikes
- ↑Favorable macro: rising healthcare spend, aging demographics, policy tailwinds
- ↑Healthy profitability, strong dividend yield and positive momentum support valuation
Bear says
- ↓Stellara expected to follow Humira’s erosion curve, pressuring immunology sales
- ↓Intensifying oncology competition may limit uptake of new therapies
- ↓Regulatory approval delays for key pipeline drugs could hit timelines
- ↓$55 B capital plan in U.S. manufacturing/R&D risks margin compression
- ↓13F ownership decline signals reduced institutional conviction
- ↓Negative earnings yield and weak growth factors flag potential value-trap
Investment themes with JNJ
Companies paying above-average dividends
Companies with strong fundamentals and stability
Drug development driving global healthcare solutions
Services and products for aging population
Earnings Call · Q2 2025 · Mgmt. Guidance